Funded Biomaterial Production Initiatives

Modern Synthesis, a London-based biotechnology company, has raised $5.5 million in an oversubscribed funding round led by Extantia Capital, with contributions from Artesian and Collaborative Fund. This capital infusion will support the company's efforts to scale production at its pilot facility and meet the growing demand from fashion brands seeking sustainable material alternatives. Modern Synthesis' technology transforms nanocellulose, a robust fibre derived from natural fermentation, into high-quality substitutes for animal leather, synthetic leather, and plastic-coated textiles. The company's scalable process enhances the inherent properties of nanocellulose, which is significantly stronger than steel at the nanofibre level, resulting in durable, plastic-free materials.

The funding will enable Modern Synthesis to expand its material offerings and address the anticipated shortage of low-impact raw materials in the fashion industry. With over 35 impending sustainability-linked regulations expected to reshape the sector, brands that fail to transition to lower-impact materials risk significant financial consequences. Modern Synthesis aims to provide these brands with sustainable solutions that do not compromise on performance, offering novel textures, appearances, and functionalities. The company's collaboration with Danish fashion label GANNI on a prototype handbag demonstrates its potential to revolutionize traditional manufacturing processes and drive real impact at scale.

Image Credit: Shutterstock